1-(2,3-dihydroimidazo<2,1-b>thiazol-6-yl)ethanone

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 1-(2,3-dihydroimidazo<2,1-b>thiazol-6-yl)ethanone
• 英文别名: 1-(2,3-Dihydroimidazo[2,1-b]thiazol-6-yl)ethanone；1-(2,3-dihydroimidazo[2,1-b][1,3]thiazol-6-yl)ethanone
• 化学式: C₇H₈N₂OS
• 分子量: 168.219
• InChiKey: FWVPAEXGJNZJGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  60.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-(2,3,5,6-tetrahydroimidazo<2,1-b>thiazol-6-yl)ethanone 反应 672.0h， 生成 1-(2,3-dihydroimidazo<2,1-b>thiazol-6-yl)ethanone
  参考文献：
  名称：

  Synthesis of 2,3,5,6-Tetrahydroimidazo[2,1-b]thiazoles

  摘要：

  The reactions of 2-amino-2-thiazoline with alkylating and acylating agents give initial reaction on the endocyclic nitrogen. Acyl groups, however, readily rearrange to the exocyclic nitrogen to give the products usually observed in these reactions. These observations clear up a considerable amount of confusion in the literature and lead to the efficient synthesis of 2,3,5,6-tetrahydroimidazo[2,1-b]thiazoles.

  DOI：

  10.3987/com-94-6838

文献信息

• Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
  申请人：Altenbach J. Robert

  公开号：US20050272736A1

  公开（公告）日：2005-12-08

  Compounds of formula (I) wherein R 1 or R 2 is a tricyclic or bicyclic ring, each of which contains at least two heteroatoms, and R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, X, X′, Y, Y′, Z, and Z′ are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  式（I）中R1或R2为含有至少两个杂原子的三环或二环环，其中R1、R2、R3、R3a、R3b、R4、R5、L、X、X′、Y、Y′、Z和Z′如本文所定义，在预防或改善组织胺-3受体配体引起的病症或紊乱方面具有治疗作用。还公开了包含组织胺-3受体配体的药物组合物，使用这类化合物和组合物的方法，以及制备符合式（I）范围内化合物的过程。
• Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
  申请人：Altenbach J. Robert

  公开号：US20050256309A1

  公开（公告）日：2005-11-17

  Compounds of formula (I) wherein R 1 or R 2 is a tricyclic or bicyclic ring, each of which contains at least two heteroatoms, and R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, X, X′, Y, Y′, Z, and Z′ are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  式（I）中R1或R2为含有至少两个杂原子的三环或二环环，其中R1、R2、R3、R3a、R3b、R4、R5、L、X、X′、Y、Y′、Z和Z′如本文所定义，在预防或改善组织胺-3受体配体引起的病症或紊乱方面具有治疗作用。还公开了包含组织胺-3受体配体的药物组合物，使用这类化合物和组合物的方法，以及制备符合式（I）范围内化合物的方法。
• 2-(IMIDAZOL-4-YL)CARBAPENEME DERIVATIVES, INTERMEDIATES THEREOF AND USE AS ANTIBACTERIALS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0785937A1

  公开（公告）日：1997-07-30
• TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS
  申请人：ABBOTT LABORATORIES

  公开号：EP1751130A2

  公开（公告）日：2007-02-14
• US7205316B2
  申请人：——

  公开号：US7205316B2

  公开（公告）日：2007-04-17